Polymer-based combination conjugates for the treatment of triple negative breast cancer: From rational design to preclinical evaluation

2018

Among breast cancer subtypes, triple negative breast cancer (TNBC) represents around 15-20% of newly diagnosed cancer cases. Together with heterogeneous behavior among single patients, TNBC presents with a complex molecular landscape, low detection rate, and an aggressive and highly proliferative profile and these characteristics provide for the poor prognosis of TNBC patients. The lack of hormonal receptor (ER, PR, and HER2) expression impedes the administration of targeted therapies, and for this reason, the development of novel therapies for TNBC represents a primary clinical need. Research into the development of polymer conjugates for the treatment of TNBC falls into four main areas: i…